Status:
COMPLETED
A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Locally Advance Breast Cancer (LABC)
Metastatic Breast Cancer (MBC)
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
Brief Summary
This is a prospective, multi-center, open-label, phase Ib/ II study (two parts) with patients that have locally advanced or metastatic HER2+ breast cancer. The first part (phase Ib) will investigate t...
Eligibility Criteria
Inclusion
- Patient is a female ≥ 18 years of age
- Patient has a histologically and/or cytologically confirmed diagnosis of HER2-positive invasive breast cancer with inoperable locally advanced or metastatic disease
- Patients with controlled or asymptomatic CNS metastases are eligible
- Patient has adequate bone marrow and organ functions, and has recovery from all clinically significant toxicities related to prior anti-neoplastic therapies
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelets ≥ 100 x 109/L
- Hemoglobin (Hgb) ≥ 9.0 g/dL
- INR ≤ 2
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN (or ≤ 5.0 x ULN if liver metastases are present)
- Total serum bilirubin ≤ 1.5 x ULN (in patients with known Gilbert Syndrome, a total bilirubin ≤ 3.0 x ULN, with direct bilirubin ≤ 1.5 x ULN)
- Serum creatinine ≤ 1.5 x ULN
- Fasting plasma glucose (FPG) ≤ 140mg/dL \[7.8 mmol/L\]
- HbA1c ≤ 8%
- Patient has received prior trastuzumab (alone or in combination) but NO more than 3 prior cytotoxic chemotherapy lines
- Prior endocrine and radiotherapy allowed
- Patient has ECOG performance status of 0-2 (Phase Ib) or 0-1 (Phase II)
- Additional inclusion criteria for phase II:
- Available tumor tissue (archival or fresh) for biomarker analysis; known PI3K activation status
- At least one measurable lesion as per RECIST 1.1
- Patient has received prior treatment with a taxane
- Patient has "trastuzumab-resistance disease" defined as:
- Recurrence while on trastuzumab (or T-DM1) or within 12 months since the last infusion in the adjuvant setting
- Progression while on or within 4 weeks since the last infusion of trastuzumab (or T-DM1) in the locally advanced or metastatic setting
Exclusion
- Previous treatment with PI3K and/or mTOR inhibitors
- Symptomatic/uncontrolled Central Nervous System (CNS) metastases
- Concurrent malignancy or malignancy in the last 3 years prior to enrollment
- Wide field radiotherapy ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to starting study drug
- Active cardiac disease (e.g. LVEF less than institutional lower limit of normal, QTcF \> 480 msec, unstable angina pectoris, ventricular, supraventricular or nodal arrhythmias)
- Inadequately controlled hypertension
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BEZ235
- Treatment at start of study treatment with drugs with a known risk to induce Torsades de Pointes, moderate and strong inhibitors or inducers of isoenzyme CYP3A4, warfarin and coumadin analogues, LHRH agonists
- Intolerance or contraindications to trastuzumab treatment
- Pregnant or nursing (lactating) woman
- Additional exclusion criteria for phase II:
- Prior treatment with capecitabine and lapatinib
- Intolerance or contraindications to capecitabine and lapatinib
- Previous treatment with HER-2 targeted agents other than trastuzumab or T-DM1
- Peripheral neuropathy ≥ Grade 2
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01471847
Start Date
February 1 2012
End Date
June 1 2012
Last Update
December 9 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Madrid, Spain, 28050
2
Novartis Investigative Site
Leicester, United Kingdom, LE1 5WW
3
Novartis Investigative Site
Manchester, United Kingdom, M20 2BX